CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
-17.51%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$942M
AUM Growth
+$942M
(-12%)
Cap. Flow
+$125M
Cap. Flow
% of AUM
13.31%
Top 10 Holdings %
Top 10 Hldgs %
58.05%
Holding
39
New
8
Increased
12
Reduced
8
Closed
1
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$35.7M |
| 2 |
Revolution Medicines
RVMD
|
$28.9M |
| 3 |
Twist Bioscience
TWST
|
$21.4M |
| 4 |
Gilead Sciences
GILD
|
$13.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$11.3M |
Top Sells
| 1 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$51.5M |
| 2 |
Illumina
ILMN
|
$8.19M |
| 3 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$7.31M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$4.73M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
$2.19M |
Sector Composition
| 1 | Healthcare | 92.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $90.6M | 9.62% | 1,550,000 +610,000 | +65% | +$35.7M |
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $65.5M | 6.96% | 670,000 | – | – |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $63.7M | 6.76% | 585,000 +70,000 | +14% | +$7.62M |
|
4
Fate Therapeutics
FATE
$120M
| $56.6M | 6.01% | 2,550,000 | – | – |
|
5
Codexis
CDXS
$246M
| $56.6M | 6.01% | 5,073,780 | – | – |
|
|
BLUE
6
DELISTED
bluebird bio
BLUE
| $50.8M | 5.39% | 1,105,000 +135,000 | +14% | +$6.2M |
|
|
NVTA
7
DELISTED
Invitae Corporation
NVTA
| $47.6M | 5.05% | 3,478,388 -160,000 | -4% | -$2.19M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $46.6M | 4.95% | 995,000 -10,000 | -1% | -$469K |
|
9
Agios Pharmaceuticals
AGIO
$2.19B
| $38M | 4.03% | 1,070,000 +245,000 | +30% | +$8.69M |
|
|
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $30.8M | 3.27% | 980,000 -232,734 | -19% | -$7.31M |
|
|
11
Twist Bioscience
TWST
$1.63B
| $30.6M | 3.25% | 1,000,000 +700,000 | +233% | +$21.4M |
|
|
12
Revolution Medicines
RVMD
$7.1B
| $28.9M | 3.07% | +1,319,536 | New | +$28.9M |
|
13
CareDx
CDNA
$727M
| $28.3M | 3% | 1,294,335 +94,335 | +8% | +$2.06M |
|
14
Alector
ALEC
$238M
| $26M | 2.76% | 1,076,039 | – | – |
|
15
Denali Therapeutics
DNLI
$2.23B
| $25.5M | 2.7% | 1,455,000 +205,000 | +16% | +$3.59M |
|
16
BioLife Solutions
BLFS
$1.2B
| $23.5M | 2.49% | 2,468,571 | – | – |
|
17
Adaptive Biotechnologies
ADPT
$2.01B
| $22M | 2.34% | 793,125 +330,000 | +71% | +$9.17M |
|
18
Dianthus Therapeutics
DNTH
$759M
| $18.7M | 1.98% | 2,971,034 -127,087 | -4% | -$798K |
|
|
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.3M | 1.63% | 300,000 | – | – |
|
20
Fulcrum Therapeutics
FULC
$351M
| $14.4M | 1.53% | 1,209,285 -30,000 | -2% | -$358K |
|
|
GNMK
21
DELISTED
GenMark Diagnostics, Inc
GNMK
| $13.9M | 1.47% | 3,365,000 | – | – |
|
|
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $13.2M | 1.4% | 2,270,000 +110,000 | +5% | +$640K |
|
|
23
Gilead Sciences
GILD
$140B
| $13.1M | 1.39% | +175,000 | New | +$13.1M |
|
|
24
CRISPR Therapeutics
CRSP
$4.71B
| $11.3M | 1.2% | +266,430 | New | +$11.3M |
|
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| $11.1M | 1.17% | 385,000 +155,000 | +67% | +$4.45M |
|